Back to results
US 2026/0218136 A1Published application
Recombinant retrovirus, compositions, and methods of use
AssigneeKelonia Therapeutics, Inc.
InventorsKevin M. Friedman, Michael J. McDonald
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for transducing immune effector cells in vivo with a recombinant retrovirus comprising a polynucleotide encoding a chimeric antigen receptor and a multipartite cell surface receptor.
Claims54
A recombinant retrovirus comprising:
- (a) a viral envelope comprising (i) one or more mutated viral envelope glycoproteins that retain fusogenic activity and lack cognate receptor binding activity and (ii) a non-viral membrane-bound tropism polypeptide, and
- (b) a recombinant retroviral vector comprising a polynucleotide encoding a promoter operably linked to a polynucleotide encoding a chimeric antigen receptor (CAR) that binds CD19, CD20, CD22, CD3δ, CD79a, CD79b, GPCR5D, or BCMA and a polynucleotide encoding a modular cell surface receptor;
- wherein the recombinant retrovirus transduces an immune effector cell in vivo.
A method of making a recombinant retrovirus comprising:
- a) transfecting the host cell with one or more polynucleotides that express retroviral gag-pol, one or more mutated viral envelope glycoproteins that retain fusogenic activity and lack cognate receptor binding activity, a non-viral membrane-bound tropism polypeptide, and optionally rev and a transfer vector encoding the recombinant retroviral vector of any of the preceding claims;
- and b) culturing the transduced cell for about 1 to 3 days to produce the recombinant retrovirus.
Dependencies are inferred from the claim text.